Related references
Note: Only part of the references are listed.Neoadjuvant pembrolizumab improves eventfree survival in melanoma
T. Schwarz
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2023)
Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma
Sapna P. Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2023)
Discovery of Small-Molecule Inhibitors of the PD-1/PD-L1 Axis That Promote PD-L1 Internalization and Degradation
Tianyu Wang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre double-blind, randomised, phase 3 trial
Georgina Long et al.
LANCET ONCOLOGY (2022)
RASA2 ablation in T cells boosts antigen sensitivity and long-term function
Julia Carnevale et al.
NATURE (2022)
Quantitative and Spatial Analysis of CD8+/PD-1 Tumor-Infiltrating Lymphocytes as a Predictive Biomarker for Clinical Response of Melanoma In-Transit Metastases to Topical Immunotherapy
Sophia Haywood et al.
ANNALS OF SURGICAL ONCOLOGY (2021)
Emerging insights on functions of the anthelmintic flubendazole as a repurposed anticancer agent
Levon M. Khachigian
CANCER LETTERS (2021)
Emerging Role of Ubiquitination in the Regulation of PD-1/PD-L1 in Cancer Immunotherapy
Xiaoli Hu et al.
MOLECULAR THERAPY (2021)
Flubendazole, FDA-approved anthelmintic, elicits valid antitumor effects by targeting P53 and promoting ferroptosis in castration-resistant prostate cancer
Xumin Zhou et al.
PHARMACOLOGICAL RESEARCH (2021)
Early Growth Response-1, an Integrative Sensor in Cardiovascular and Inflammatory Disease
Levon M. Khachigian
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2021)
The Drug Repurposing for COVID-19 Clinical Trials Provide Very Effective Therapeutic Combinations: Lessons Learned From Major Clinical Studies
Chiranjib Chakraborty et al.
FRONTIERS IN PHARMACOLOGY (2021)
Emerging concepts in PD-1 checkpoint biology
Kristen E. Pauken et al.
SEMINARS IN IMMUNOLOGY (2021)
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Lei Zhong et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)
Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018
Olivier J. Wouters et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Mixed lineage kinase 3 inhibition induces T cell activation and cytotoxicity
Sandeep Kumar et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
An analysis of mitotic catastrophe induced cell responses in melanoma cells exposed to flubendazole
K. Rudolf et al.
TOXICOLOGY IN VITRO (2020)
The anthelmintic flubendazole blocks human melanoma growth and metastasis and suppresses programmed cell death protein-1 and myeloid-derived suppressor cell accumulation
Yue Li et al.
CANCER LETTERS (2019)
Carbonyl Reduction of Flubendazole in the Human Liver: Strict Stereospecificity, Sex Difference, Low Risk of Drug Interactions
Vladimir Kubicek et al.
FRONTIERS IN PHARMACOLOGY (2019)
Tissue-resident memory CD8+ T cells promote melanoma-immune equilibrium in skin
Simone L. Park et al.
NATURE (2019)
c-Jun overexpression in CAR T cells induces exhaustion resistance
Rachel C. Lynn et al.
NATURE (2019)
Administration of Hypoxia-Activated Prodrug Evofosfamide after Conventional Adjuvant Therapy Enhances Therapeutic Outcome and Targets Cancer-Initiating Cells in Preclinical Models of Colorectal Cancer
Jennifer Haynes et al.
CLINICAL CANCER RESEARCH (2018)
Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study
Margaret K. Callahan et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Multiplex immunohistochemistry accurately defines the immune context of metastatic melanoma
H. Halse et al.
SCIENTIFIC REPORTS (2018)
The diverse functions of the PD1 inhibitory pathway
Arlene H. Sharpe et al.
NATURE REVIEWS IMMUNOLOGY (2018)
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
An Isogenic Human ESC Platform for Functional Evaluation of Genome-wide-Association-Study-Identified Diabetes Genes and Drug Discovery
Hui Zeng et al.
CELL STEM CELL (2016)
Genetic and Epigenetic Regulation of PD-1 Expression
Alexander P. R. Bally et al.
JOURNAL OF IMMUNOLOGY (2016)
Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth
Sonja Kleffel et al.
CELL (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
limma powers differential expression analyses for RNA-sequencing and microarray studies
Matthew E. Ritchie et al.
NUCLEIC ACIDS RESEARCH (2015)
Flubendazole, FDA-approved anthelmintic, targets breast cancer stem-like cells
Zhi-Jie Hou et al.
ONCOTARGET (2015)
Blimp-1 represses CD8 T cell expression of PD-1 using a feed-forward transcriptional circuit during acute viral infection
Peiyuan Lu et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2014)
Crucial Role for Early Growth Response-1 in the Transcriptional Regulation of miR-20b in Breast Cancer
Dongping Li et al.
ONCOTARGET (2013)
Role of PI3K/Akt signaling in memory 038 T cell differentiation
Eui Ho Kim et al.
FRONTIERS IN IMMUNOLOGY (2013)
Activator protein 1 suppresses antitumor T-cell function via the induction of programmed death 1
Gang Xiao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
The role of the PI3K signaling pathway in CD4(+) T cell differentiation and function
Jonathan M. Han et al.
FRONTIERS IN IMMUNOLOGY (2012)
Drug repositioning for personalized medicine
Yvonne Y. Li et al.
GENOME MEDICINE (2012)
The antihelmintic flubendazole inhibits microtubule function through a mechanism distinct from Vinca alkaloids and displays preclinical activity in leukemia and myeloma
Paul A. Spagnuolo et al.
BLOOD (2010)
A scaling normalization method for differential expression analysis of RNA-seq data
Mark D. Robinson et al.
GENOME BIOLOGY (2010)
Treatment of arthritis with a selective inhibitor of c-Fos/activator protein-1
Yukihiko Aikawa et al.
NATURE BIOTECHNOLOGY (2008)
Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond
Hossein A. Ghofrani et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
PD-L2 is a second ligand for PD-I and inhibits T cell activation
Y Latchman et al.
NATURE IMMUNOLOGY (2001)
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
GJ Freeman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Share Paper
